Goldman Sachs Analyst Anticipates Clarity On Vertex's Investment Roadmap And Product Monetization At Investor Day
Goldman Sachs analyst expects positive updates from Vertex's first Investor Day as a public company on March 19, reiterates ...
Where Will Vertex Pharmaceuticals Be in 10 Years?
Vertex Pharmaceuticals generated more than $11 billion in product revenue last year thanks to its dominance in cystic ...
A Closer Look at Vertex Pharmaceuticals's Options Market Dynamics
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...
Investing Snacks4d
Vertex EVP Sells $1.62M in Stock Amid Market Highs
Vertex Pharmaceuticals EVP Ourania Tatsis sold 3,242 shares worth $1.62 million under a pre-arranged plan. The sale, executed on March 10, 2025, priced each share at $499.99, with Tatsis still holding ...